Larimar Therapeutics Inc (LRMR)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Larimar Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 278.9% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.39 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.45 | – | 1 | – | -5,980.10 | -22 | -22 |
| 2025: Q1 | -0.46 | – | 0 | – | – | -27 | -27 |
| 2025: Q2 | -0.41 | – | 0 | – | – | -19 | -19 |
| 2025: Q3 | -0.61 | – | 0 | – | – | -29 | -29 |
| 2025: Q4 | -0.73 | – | 0 | -100.00 | – | -39 | -39 |
| 2026: Q1 | -0.35 | – | 0 | – | – | -45 | -45 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Larimar Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
| Employees | 71 |
|---|---|
| Headquarters | Bala Cynwyd, PA |
| Website | larimartx.com |
| IPO Date | 19. Jun 2014 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Carole S. Ben-Maimon M.D. | CEO, President & Director | 1959 |
| Michael Celano CPA | Secretary & CFO | 1959 |
| Gopi Shankar M.B.A., Ph.D. | Chief Development Officer | 1971 |
| John Berman | Vice President of Finance & Administration | – |
| Jennifer Spokes Johansson | Vice President of Legal & Compliance | – |
| Russell G. Clayton Sr., D.O. | Chief Medical Officer | 1961 |
| Francis Michael Conway CPA | VP & Controller | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 6. Jul 2026 | Hamilton Thomas Edward | Director | Buy | 50,000 | 3.34 | 166,890 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.